Esperion Therapeutics, Inc. and Daiichi Sankyo Europe GmbH announced a $125 million amendment to their collaboration, which includes anamicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products. DSE has agreed to pay Esperion $100 million in mid-January ahead of an anticipated Type II(a) variation approval by the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bem Pedoic acid and ezetimibe) Tablet. DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.

The legal action pending in the United States District Court for the Southern District of New York will be dismissed. The parties also agreed, as part of the resolution: for Esperion to transition to DSE manufacturing and supply responsibilities in Europe and other territories, resulting in significant cost savings and efficiencies for both companies. to expand their collaboration in Europe and other territories, to include the potential development and commercialization of a triple formulation product comprising bempedoic acid, ezetimibe and a statin, which could represent significant long-term value for the collaboration.

for DSE to now lead all regulatory communications with the EMA regarding the pending applications. Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction. The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.